References
- Centers for Disease Control and Prevention, Hall E, Wodi AP, Hamborsky J, et al., editors. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, D.C: Public Health Foundation; 2021.
- Shinjoh M, Yamaguchi Y, Furuichi M, et al. Recent trends in pediatric bacterial meningitis in Japan, 2016-2018 - S. agalactiae has been the most common pathogen. J Infect Chemother. 2020 Oct;26:(10):1033–1041.
- Furuichi M, Yaginuma M, Shinjoh M, et al. Extended-spectrum β-lactamase-producing Escherichia coli in neonates and listeria monocytogenes in young children with bacterial meningitis in Japan. J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):165–168. doi: 10.1093/jpids/piac135
- Yanagihara K, Kosai K, Mikamo H, et al. Serotype distribution and antimicrobial susceptibility of streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan. Int J Infect Dis. 2021 Jan;102:260–268. doi: 10.1016/j.ijid.2020.10.017
- Epidemiological information of invasive pneumococcal infection in children and adults. [overview of FY2013~FY2022] 2022. Available from: https://ipd-information.com/?page_id=46
- Pimenta F, Moiane B, Gertz RE Jr., et al. New pneumococcal serotype 15D. J Clin Microbiol. 2021 Apr 20;59(5):e00329–21. doi: 10.1128/JCM.00329-21
- Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. MBio. 2020 May 19;11(3):e00937–20. doi: 10.1128/mBio.00937-20
- Hausdorff WP, Hanage WP. Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–374. doi: 10.1080/21645515.2015.1118593
- Yahiaoui RY, Bootsma HJ, den Heijer CD, et al. Distribution of serotypes and patterns of antimicrobial resistance among commensal streptococcus pneumoniae in nine European countries. BMC Infect Dis. 2018 Aug 29;18(1):440. doi: 10.1186/s12879-018-3341-0
- Kay EJ, Yates LE, Terra VS, et al. Recombinant expression of streptococcus pneumoniae capsular polysaccharides in Escherichia coli. Open Biol. 2016 Apr;6:(4):150243.
- Pfizer. Full prescribing information-PREVNAR 20® 2023. 2023 Apr. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=15428
- MSD Corporation. 15-valent pneumococcal conjugate vaccine “vacnyvance ® aqueous suspension syringe” obtained additional approval for pediatric indication 2023. 2023 Aug 31. Available from: https://www.msd.co.jp/news/product-news-20230626-2/
- Levy C, Varon E, Ouldali N, et al. Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine. PLOS ONE. 2019;14(2):e0211712. doi: 10.1371/journal.pone.0211712
- Garcia Quesada M, Yang Y, Bennett JC, et al. Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE project. Microorganisms. 2021 Apr 1;9(4):738. doi: 10.3390/microorganisms9040738
- Ekinci E, Desmet S, Van Heirstraeten L, et al. Streptococcus pneumoniae serotypes carried by young children and their association with acute otitis media during the period 2016-2019. Front Pediatr. 2021;9:664083. doi: 10.3389/fped.2021.664083
- De Miguel S, Latasa P, Yuste J, et al. Age-dependent serotype-associated case-fatality rate in invasive pneumococcal disease in the autonomous community of Madrid between 2007 and 2020. Microorganisms. 2021 Nov 3;9(11):2286. doi: 10.3390/microorganisms9112286
- Cho EY, Choi EH, Kang JH, et al. Early changes in the serotype distribution of invasive pneumococcal isolates from children after the introduction of extended-valent pneumococcal conjugate vaccines in Korea, 2011-2013. J Korean Med Sci. 2016 Jul;31:(7):1082–1088.
- Balsells E, Guillot L, Nair H, et al. Serotype distribution of streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLOS ONE. 2017;12(5):e0177113. doi: 10.1371/journal.pone.0177113
- Amin-Chowdhury Z, Collins S, Sheppard C, et al. Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014-2018. Clin Infect Dis. 2020 Nov 5;71(8):e235–e243. doi: 10.1093/cid/ciaa043
- Ministry of Health Labour and Welfare (MHLW). [Basic plan for immunization] 2014. 21 Nov 2014 [2023 Sep 7]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/kihonteki_keikaku/index.html
- Lytle D, Grajales Beltrán AG, Perdrizet J, et al. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Hum Vaccin Immunother. 2023 Aug;19:(2):2257426.
- Warren S, Barmpouni M, Kossyvaki V, et al. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to higher-valent options in Greek infants. Vaccines (Basel). 2023 Aug 15;11(8):1369. doi: 10.3390/vaccines11081369
- Tajima A, Abe M, Weaver J, et al. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan. J Med Econ. 2023 Jan;26:(1):1034–1046.
- Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis. 2014 Mar;58(6):854–864. doi: 10.1093/cid/cit800
- Ministry of Health Labour and Welfare (MHLW). Pneumococcal vaccine working team. Pneumococcal conjugate vaccine for children working team report. 2018 [2023 Sep 4]. Available from: https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000207088_1.pdf
- Løchen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2020 Jan;26(1):60–70. doi: 10.1016/j.cmi.2019.04.026
- Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017 Jan;5:(1):e51–e59.
- OECD. Exchange rates 2022. Available from: https://data.oecd.org/conversion/exchange-rates.htm
- Fukuda T, Shiroiwa T. Cost effectiveness evaluation of health care technologies in Japan: new HTA system and the role of C2H. J Natl Inst Public Health. 2021;70(1):22–27.
- Hasegawa M, Komoto S, Shiroiwa T, et al. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020 Jan;23:(1):43–51.
- Center for Outcomes Research and Economic Evaluation for Health- National Institute of Public Health (C2H Japan). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Version 3 2022. 2022 Jan 19 [cited 2022 Apr 12]. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
- Ministry of Health Labour and Welfare (MHLW). [Number of people who received routine immunizations] 2021. 2023 Aug 29. Available from: https://www.mhlw.go.jp/topics/bcg/other/5.html
- Ministry of Internal Affairs and Communications. Population estimates (as of October 1st, 2021): Statistics Bureau; 2022. 2023 Jun 7. Available from: https://www.stat.go.jp/data/jinsui/2021np/index.html
- National Institute of Infectious Diseases. [Annual report of the National Epidemiological Surveillance of infectious diseases (NESID): 2014–2021] 2022. 2022 Feb 3 [2023 Jul 6]. Available from: https://www.niid.go.jp/niid/en/component/search/?searchword=NESID%E5%B9%B4%E5%A0%B1%E9%9B%86%E8%A8%88%E8%A1%A8&ordering=newest&searchphrase=all&limit=50
- JMDC. JMDC Real World Tokyo: JMDC; 2022 [2023 Jun 7]. Available from: https://www.eng.phm-jmdc.com/
- Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLOS ONE. 2015 Mar 30;10(3):e0122247. doi: 10.1371/journal.pone.0122247
- National Institute of Infectious Diseases and Health Service Bureau. [Infectious agents surveillance report (IASR) Vol.44 No.1 2023 January]. 2023 Jun 7. Available from: https://www.niid.go.jp/niid/images/idsc/iasr/44/515.pdf
- Chang B, Tamura K, Fujikura H, et al. Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan. Sci Rep. 2022 Feb 23;12(1):3066. doi: 10.1038/s41598-022-06950-w
- Shinjoh M, Yamaguchi Y, Iwata S. Pediatric bacterial meningitis in Japan, 2013-2015 - 3-5 years after the wide use of Haemophilus influenzae type b and Streptococcus pneumoniae conjugated vaccines. J Infect Chemother. 2017 Jul;23(7):427–438. doi: 10.1016/j.jiac.2017.02.014
- Nakano S, Fujisawa T, Ito Y, et al. Nationwide surveillance of paediatric invasive and non-invasive pneumococcal disease in Japan after the introduction of the 13-valent conjugated vaccine, 2015-2017. Vaccine. 2020 Feb 11;38(7):1818–1824. doi: 10.1016/j.vaccine.2019.12.022
- Ministry of Health Labour and Welfare (MHLW). [Overview of patient survey 2020] 2022. 2023 Jun 7. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/kanja/20/index.html
- Ministry of Health Labour and Welfare (MHLW). [Vital statistics 2014–2020] 2022. 2023 May 26 [2023 Jun 7]. Available from: https://www.mhlw.go.jp/toukei/list/81-1.html
- Iwata S, Takata M, Morozumi M, et al. Drastic reduction in pneumococcal meningitis in children owing to the introduction of pneumococcal conjugate vaccines: longitudinal analysis from 2002 to 2016 in Japan. J Infect Chemother. 2021 Apr;27:(4):604–612.
- Iwata S, Hanada S, Takata M, et al. Risk factors and pathogen characteristics associated with unfavorable outcomes among adults with pneumococcal meningitis in Japan, 2006 to 2016. J Infect Chemother. 2023 Jul;29:(7):637–645.
- Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004 Oct 22;22(31–32):4203–4214.
- Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012 Oct 26;345(oct26 1):e6879. doi: 10.1136/bmj.e6879
- Stoecker C, Kim L, Gierke R, et al. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016 Aug;31:(8):901–908.
- Oostenbrink R, AM HA, Essink-Bot ML. The EQ-5D and the health utilities index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002 Aug;55(8):791–799. doi: 10.1016/S0895-4356(02)00448-1
- Ikeda T, Yanagawa S, Murakami K, et al. Cost-utility analysis of a disability prevention program for community-dwelling older adults with mild disability in the urban area of Tokyo, Japan. Japanese J Human Sci Health-Soc Serv. 2017 Mar 21;23(2):3–12.
- Ministry of Health Labour and Welfare (MHLW). [Guidelines for evaluating the cost-effectiveness of vaccination]. Available from: https://www.mhlw.go.jp/stf/shingi/2r98520000014ryv-att/2r98520000014sdi.pdf
- Ministry of Health Labour and Welfare (MHLW). Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein] suspension for intramuscular injection. (in Japanese). Available from: https://www.mhlw.go.jp/stf/shingi/2r985200000371fc-att/2r985200000371td.pdf
- MDV. MDV Database Overview Tokyo: MDV; 2023 Jun 7. Available from: https://en.mdv.co.jp/about-mdv-database/mdv-database-overview/
- Suaya JA, Ohno T, Hilton B, et al. Cost-effectiveness analysis of 13-valent versus 10-valent pneumococcal conjugate vaccines as part of routine infant pneumococcal vaccination program in Japan. Jpn J Pediatr. 2015 06;68(6):1197–1217.
- Ministry of Health Labour and Welfare (MHLW). [Basic survey on wage structure in 2022] (in Japanese). 2022. Available from: https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450091&tstat=000001011429&cycle=0&tclass1=000001202310&tclass2=000001202312&tclass3=000001202328&tclass4val=0
- National Institute of population and social security research. [population projections for Japan (2023 revision): median birth (median death)]: National Institute of population and social security Research; 2023. 2023 Jun 7. Available from: https://www.ipss.go.jp/pp-zenkoku/j/zenkoku2023/db_zenkoku2023/db_r5_suikeikekka_1.html
- Epidemiological information of invasive pneumococcal infection in children and adults. Epidemiological status in FY2022. 2022. Available from: https://ipd-information.com/?page_id=55
- Ministry of Health Labour and Welfare (MHLW). [Overview of the simplified life tables in 2021] 2021. 2023 Jun 7. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/life/life21/index.html
- Savulescu C, Krizova P, Valentiner-Branth P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022 Jun 23;40(29):3963–3974. doi: 10.1016/j.vaccine.2022.05.011
- Patterson S, Webber C, Patton M, et al. A post hoc assessment of duration of protection in CAPiTA (community acquired pneumonia immunization trial in adults). Trials Vaccinol. 2016 Mar 7;5:92–96.
- Perdrizet J, Horn EK, Hayford K, et al. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England and Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12:(5):1351–1364.
- Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021 Aug;24(8):1193–1202. doi: 10.1016/j.jval.2021.03.010
- Ministry of Health Labour and Welfare (MHLW). [Precipitated 13-valent pneumococcal conjugate vaccine (non-toxic mutant diphtheria toxin conjugate) Prevenar 13Ⓡ Aqueous Suspension Injection] 2013. 2023 Sep 2. Available from: https://www.mhlw.go.jp/stf/shingi/2r985200000371fc.att/2r985200000371td.pdf
- Ministry of Health Labour and Welfare (MHLW). [Pneumococcal vaccine for children] 2023. 2023 Sep 2. Available from: https://www.mhlw.go.jp/content/10900000/001139474.pdf
- Centers for Disease Control and Prevention. Vaccines for children program (VFC). CDC vaccine price list. 2023. Available from: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html
- Ministry of Health Labour and Welfare (MHLW). [Medical service fee information] 2023. 2023 Jun 7. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/newpage_21053.html
- Igarashi A, Hirose E, Kobayashi Y, et al. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines. 2021 Sep;20:(9):1153–1165.
- Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
- Ministry of Health Labour and Welfare (MHLW). Health labour sciences research grant. [description of invasive pneumococcus and Haemophilus influenzae infections in the infectious disease trend survey and comparison with the urushibara group in children]. 2015. Available from: https://mhlw-grants.niph.go.jp/system/files/2014/143121/201420044A/201420044A0001.pdf
- Yamanaka N, Hotomi M, Sugita R. Disease-burden of acute otitis media on children and cost-effectiveness of pneumococcal conjugate vaccine in Japan. J Pediat Infect Dis Immuno. 2009;21:37–48.
- Goldblatt D. The indirect effect of pneumococcal conjugate vaccine. Lancet Glob Health. 2017 Jan;5(1):e6–e7. doi: 10.1016/S2214-109X(16)30338-2
- Nymark LS, Sharma T, Miller A, et al. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine. 2017 Dec 14;35(49 Pt B):6828–6841. doi: 10.1016/j.vaccine.2017.10.024
- Yamamoto T, Komiya K, Fujita N, et al. COVID-19 pandemic and the incidence of community-acquired pneumonia in elderly people. Respir Investig. 2020 Nov;58:(6):435–436.
- Yan Y, Tomooka K, Naito T, et al. Decreased number of inpatients with community-acquired pneumonia during the COVID-19 pandemic: a large multicenter study in Japan. J Infect Chemother. 2022 May;28:(5):709–713.
- Kitano T, Aoki H. The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: a secondary impact of COVID-19. Comput Biol Med. 2021 Jun;133:104429. doi: 10.1016/j.compbiomed.2021.104429
- Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006 Jun;25:(6):494–501.
- Jiang S, Wang Y, Si L, et al. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. BMJ Glob Health. 2022 Aug;7:(8):e009777.
- Kobayashi M Centers for Disease Control and Prevention, national center for immunization & respiratory diseases. Evidence to recommendations framework and policy options: use of 20-valent pneumococcal conjugate vaccine in U.S. Children. 2023. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/04-Pneumococcal-Kobayashi-508.pdf
- Huang L, McDade CL, Perdrizet JE, et al. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12:(3):933–950.
- Wilson M, McDade C, Beby-Heijtel AT, et al. Assessing public health impact of four pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023 Jul;12:(7):1809–1821.
- Wilson M, Lucas A, Mendes D, et al. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023 Jun 28;11(7):1168. doi: 10.3390/vaccines11071168